Lupin is partnering with Mark Cuban Cost Plus Drug Company and the COPD Foundation, in an effort to bolster access to health care by expanding the availability of Tiotropium Bromide Inhalation Powder, ...

Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity and ...

May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following the ...

Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...

Of the hundreds of drugs that entered the U.S. market in 2024, GoodRx has named 19 of them as the most notable. Note: The chronological list does not include December approvals. 1. Dupixent (dupilumab ...

For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

A GSK drug that targets a pathway behind the lung inflammation in chronic obstructive pulmonary disease, or COPD, has won a long-awaited FDA approval, positioning the biologic medicine to reach ...

The Biden administration unveiled the next 15 drugs that will undergo Medicare negotiations Friday, just a few days before President-elect Donald Trump takes office. Ozempic and Wegovy, Novo Nordisk’s ...

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc. The Rahway pharma giant announced the deal for the biopharmaceutical company ...